Last reviewed · How we verify
Arbidol (Umifenovir)
Arbidol (Umifenovir) is a Viral fusion inhibitor Small molecule drug developed by Pharmstandard. It is currently FDA-approved for Influenza A and B prophylaxis and treatment, Acute respiratory viral infections, COVID-19 (in some markets, though efficacy remains debated).
Arbidol inhibits viral fusion by blocking the interaction between viral envelope proteins and host cell membranes, preventing viral entry into cells.
Arbidol inhibits viral fusion by blocking the interaction between viral envelope proteins and host cell membranes, preventing viral entry into cells. Used for Influenza A and B prophylaxis and treatment, Acute respiratory viral infections, COVID-19 (in some markets, though efficacy remains debated).
At a glance
| Generic name | Arbidol (Umifenovir) |
|---|---|
| Sponsor | Pharmstandard |
| Drug class | Viral fusion inhibitor |
| Target | Viral hemagglutinin (envelope protein) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Umifenovir is a broad-spectrum antiviral that targets the fusion process of enveloped viruses, including influenza and other respiratory viruses. It binds to viral hemagglutinin and prevents the conformational changes necessary for the virus to fuse with the host cell membrane, thereby blocking viral entry and infection.
Approved indications
- Influenza A and B prophylaxis and treatment
- Acute respiratory viral infections
- COVID-19 (in some markets, though efficacy remains debated)
Common side effects
- Gastrointestinal disturbances
- Headache
- Allergic reactions
Key clinical trials
- The Efficacy and Safety of Arbidol in Reducing the Frequency of AECOPD. (PHASE4)
- Severe Influenza Trial of ARbidol (PHASE3)
- Efficacy and Safety of Arbidol in the Treatment of Allergic Rhinitis (NA)
- Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Mild COVID-19 (PHASE2, PHASE3)
- Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus (PHASE4)
- The Bioequivalence Study of Umifenovir 200 mg Capsul (ATABAY, Turkey) Under Fasting Conditions (PHASE1)
- The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection (PHASE4)
- Umifenovir in Hospitalized COVID-19 Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arbidol (Umifenovir) CI brief — competitive landscape report
- Arbidol (Umifenovir) updates RSS · CI watch RSS
- Pharmstandard portfolio CI
Frequently asked questions about Arbidol (Umifenovir)
What is Arbidol (Umifenovir)?
How does Arbidol (Umifenovir) work?
What is Arbidol (Umifenovir) used for?
Who makes Arbidol (Umifenovir)?
What drug class is Arbidol (Umifenovir) in?
What development phase is Arbidol (Umifenovir) in?
What are the side effects of Arbidol (Umifenovir)?
What does Arbidol (Umifenovir) target?
Related
- Drug class: All Viral fusion inhibitor drugs
- Target: All drugs targeting Viral hemagglutinin (envelope protein)
- Manufacturer: Pharmstandard — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for Influenza A and B prophylaxis and treatment
- Indication: Drugs for Acute respiratory viral infections
- Indication: Drugs for COVID-19 (in some markets, though efficacy remains debated)
- Compare: Arbidol (Umifenovir) vs similar drugs
- Pricing: Arbidol (Umifenovir) cost, discount & access